The Canadian government has granted authorization to a startup to export psychedelic substances to Australia for medical purposes. Optimi Health Corp., has been tasked with delivering pills infused with psilocybin, a magic mushroom extract, and MDMA, under the approval of the health department.
The growing demand is not confined to the local magic mushrooms Ontario. Other countries are following Canada’s lead and beginning to investigate and authorize the medical use of serotogenic compounds.
Feel confident to buy psychedelics online in Canada and tap into your inherent potential via trustworthy sources.
[toc]Principal Points:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licenced psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions spread over five to eight weeks, with each session lasting approximately eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a fledgling company in Vancouver, is aiming to use its certification to broaden the pharmaceutical market for psychedelic drugs and secure an early advantage in the market.
Seven businesses have exported psilocybin, MDMA, or both, but only for clinical trial purposes. A representative from the Canadian health department was unable to confirm whether these exports were for regular patient use and chose not to reveal the companies for security reasons.
This milestone places Optimi among a limited group of global suppliers, with the current market trending more towards clinical than recreational uses.
What Does the Pill Contain?
Although the company has not detailed the specific mushroom used in the pill, they do work with a range of strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, home to approximately 3,000 inhabitants, is situated three hours east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
It’s estimated that 1 in 5 Australians between the ages of 16 and 85 may experience mental illness. PTSD (post-traumatic stress disorder) could potentially affect 11% of Australians during their lifetime, while anxiety disorders are prevalent in about 17% of the population.
While there are numerous methods to treat mental health conditions, they may not all be effective for each individual. Those who don’t respond to certain interventions may struggle to find a method that works for them, which can exacerbate their vulnerability.
Understanding the Process
Australia has been at the forefront of psilocybin use, allowing licensed psychiatrists to employ this controlled substance as a treatment for PTSD and treatment-resistant depression.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psychedelic mushrooms for therapeutic use. The TGA maintained that these substances are safe when used in a medically supervised setting for patients with severe mental disorders.
This change has been a game changer for many mental health professionals and researchers. The use of these substances will be strictly monitored; it’s not as simple as taking a pill and leaving.
The treatment typically involves three sessions spread over five to eight weeks. Each session lasts about eight hours, and the therapist stays with the patient the entire time.
Canada’s Role in Psilocybin Research
Canada has become a leading center for psilocybin research, significantly expanding our understanding of this compound. Health Canada, along with various institutions, is spearheading the investigation into psilocybin’s therapeutic properties in treating diverse mental health disorders.
Research institutions no longer need to classify these substances as illegal or rely on unlicensed dispensaries or mushroom stores. The government now permits certain institutions to grow psychedelic mushrooms for research purposes.
The newfound access to substances previously deemed harmful enables researchers to expand their understanding of their potential benefits for many individuals.
A Recurring Trend
First noticed in the 1950s, the potential of this field in addressing mental health disorders and substance addiction, including alcoholism, was significant. This early research was pioneered by English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer at the Weyburn Mental Hospital in Saskatchewan. The hospital saw substantial progress under the administration of then-premier Tommy Douglas, who gave the medical community considerable freedom to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer launched investigations into LSD, mescaline, and peyote as potential alternatives to extreme measures such as electroshock and lobotomy. Their research took unexpected turns, leading them to advocate for medical personnel, including doctors, nurses, and support staff, to experiment with these substances.
Research at Canadian Health Institutes
Under the auspices of the Institute of Neurosciences, Mental Health, and Addiction, the Canadian Institutes of Health Research is funding three clinical trials. These trials are designed to evaluate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress at end-of-life in advanced-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Investigating the mechanisms of psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
The funding, made possible by the Government of Canada’s Canadian Drugs and Substances Strategy (CDSS), will aid in deepening the understanding of controlled substances’ benefits.
Further Research in Psychedelics
In Vancouver, psychiatrists have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for post-traumatic stress disorder (PTSD) treatment. The trial includes three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it marks the first clinical investigation of an illegal substance.
It’s been over four decades since a new psychedelic substance was discovered.
Getting to Know Psilocybin
Psilocybin, a psychedelic compound naturally present in certain types of mushrooms, converts into psilocin when ingested. This psilocin activates serotonin 5-HT2a receptors on the brain’s cortical pyramidal cells – the primary sites for mental processing.
Currently, researchers are examining the potential of this substance to alleviate depression, anxiety, addiction, and distress associated with end-of-life, by promoting introspection and spiritual enlightenment.
Why is it Potentially Effective Against Depression, PTSD, and Other Conditions?
The active ingredient in psilocybin targets multiple areas of the brain, which could make it beneficial for treating various mental health conditions. Indeed, several patients in Canada and Australia have already undergone this therapy, and the results look promising. Side effects such as transient anxiety or elevated blood pressure have been minimal.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound partially activates serotonin receptors, specifically the 5-HT2A subtype, which play a key role in mood regulation and emotional processing.
- Modulation of Default Mode Network (DMN): The substance reduces activity within the DMN, which promotes introspection, emotional adaptability, and reduces rigid thought patterns.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of this compound stem from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressive individuals, the response to emotional stimuli is often reduced. This substance enhances positive emotional responses in the right amygdala, while minimizing or normalizing responses to negative or neutral stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: The substance enhances feelings of euphoria, emotional openness, and a sense of interconnectedness during and following the experience.
- Enhanced Emotional Processing: The psychedelic journey can help individuals safely face and process deeply held emotions, traumatic memories, or existential concerns within a supportive setting.
- Insights on Spirituality and Existence: Studies from Johns Hopkins University and Imperial College London suggests that it can foster enduring positive changes, such as augmented well-being, heightened life contentment, and spiritual growth.
What Can You Discover at Your Neighborhood Magic Mushroom Stores?
Interested in how the substance might affect your mental health? You can explore magic mushroom stores to locate a product that fits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Bolsters mood, sparks creative thinking, and ameliorates productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Supports enhanced wellness and elevates overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Induces clarity, creativity, and concentration. Comprises a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Imparts cognitive and energy advantages |
International Acceptance of Psilocybin
Canada is not the sole country advocating for the use of magic mushrooms to address mental health concerns. Countries like Australia also endorse the application of these hallucinogens to tackle issues such as depression and PTSD. They are procuring top-grade psychedelic capsules from trustworthy sources. Under suitable supervision, patients can significantly boost their life quality. Deadhead Chemist Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA have therapeutic potential by enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is effective in addressing depression and addiction.
Conversely, MDMA engenders empathy and proves beneficial in PTSD treatment. It displays promise in ameliorating emotional processing and
While this substance is controlled, it has shown therapeutic results.
Is this treatment option available to all Australians?
Not exactly. In Australia, a preliminary assessment is required to ascertain an individual’s appropriateness for using the substance. Factors such as pre-existing heart conditions and history of psychosis are taken into account. This treatment is only offered to patients who haven’t experienced improvement with conventional treatments for conditions such as depression, anxiety, or PTSD.
What is the impact of Canada exporting mushrooms?
Canada is strategically positioning itself to lead the psychedelics market, mirroring its approach to cannabis. This move could enable more companies to produce high-quality products. As a result, Canada could rise as a leading player in the hallucinogen market, boost its economy, and improve access to treatments for other nations. It would also discourage other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles You Might Find Interesting:
